Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sands Lab Inc. (411080:KRX), powered by AI.
Sands Lab Inc. is currently trading at ₩5,240. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Sands Lab Inc. on Alpha Lenz.
Sands Lab Inc.'s P/E ratio is -145.6.
“Sands Lab Inc. trades at a P/E of -145.6 (undervalued) with modest ROE of -1.1%.”
Ask for details →Sands Lab Inc. is a biotechnology company focusing on the research and development of innovative healthcare solutions. The company is specialized in creating advanced therapies and diagnostic tools that cater to the medical and pharmaceutical industries. With a commitment to improving patient outcomes, Sands Lab Inc. actively engages in pioneering research initiatives that aim to address unmet medical needs across various therapeutic areas, such as oncology, immunology, and infectious diseases. The firm employs cutting-edge technologies, including genomics, proteomics, and bioinformatics, to drive its product development pipeline. Sands Lab Inc. is well-regarded for its robust collaborations with leading academic and research institutions, further solidifying its position as a key player in the advancement of medical science. The company's contributions significantly impact the healthcare sector by enhancing treatment modalities and diagnostics, ultimately striving to elevate the quality of care available to patients globally. As biotechnology continues to expand its influence in the medical field, Sands Lab Inc. remains a critical contributor to the progress and innovation driving these advancements.
“Sands Lab Inc. trades at a P/E of -145.6 (undervalued) with modest ROE of -1.1%.”
Ask for details →Sands Lab Inc. (ticker: 411080) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $80.0B.
The current price is ₩5,240 with a P/E ratio of -145.55x and P/B of 1.48x.
ROE is -1.08% and operating margin is -15.25%. Annual revenue is $11.6B.